Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: A systematic review and meta-analysis

Rachel Jen, Stephen I. Rennard, Don D. Sin

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation in the small airways. The effect of inhaled corticosteroids (ICS) on lung inflammation in COPD remains uncertain. We sought to determine the effects of ICS on inflammatory indices in bronchial biopsies and bronchoalveolar lavage fluid of patients with COPD. Methods: We searched Medline, Embase, Cinahl, and the Cochrane database for randomized, controlled clinical trials that used bronchial biopsies and bronchoalveolar lavage to evaluate the effects of ICS in stable COPD. For each chosen study, we calculated the mean differences in the concentrations of inflammatory cells before and after treatment in both intervention and control groups. These values were then converted into standardized mean differences (SMD) to accommodate the differences in patient selection, clinical treatment, and biochemical procedures that were employed across the original studies. If significant heterogeneity was present (P, 0.1), then a random effects model was used to pool the original data; otherwise, a fixed effects model was used. Results: We identified eight original studies that met the inclusion criteria. Four studies used bronchial biopsies (n = 102 participants) and showed that ICS were effective in reducing CD4 and CD8 cell counts (SMD, -0.52 units and -0.66 units, 95% confidence interval). The five studies used bronchoalveolar lavage fluid (n = 309), which together showed that ICS reduced neutrophil and lymphocyte counts (SMD, -0.64 units and -0.64 units, 95% confidence interval). ICS on the other hand significantly increased macrophage counts (SMD, 0.68 units, 95% confidence interval) in bronchoalveolar lavage fluid. Conclusion: ICS has important immunomodulatory effects in airways with COPD that may explain its beneficial effect on exacerbations and enhanced risk of pneumonia.

Original languageEnglish (US)
Pages (from-to)587-595
Number of pages9
JournalInternational Journal of COPD
Volume7
DOIs
StatePublished - Dec 1 2012

Fingerprint

Chronic Obstructive Pulmonary Disease
Meta-Analysis
Adrenal Cortex Hormones
Inflammation
Bronchoalveolar Lavage Fluid
Bronchoalveolar Lavage
Confidence Intervals
Biopsy
Pneumonia
Lymphocyte Count
CD4 Lymphocyte Count
Patient Selection
Neutrophils
Randomized Controlled Trials
Macrophages
Databases
Control Groups
Therapeutics

Keywords

  • Bronchial biopsies
  • Bronchoalveolar lavage
  • Chronic obstructive pulmonary disease
  • Inflammation
  • Inflammatory markers
  • Inhaled corticosteroids
  • Meta-analysis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease : A systematic review and meta-analysis. / Jen, Rachel; Rennard, Stephen I.; Sin, Don D.

In: International Journal of COPD, Vol. 7, 01.12.2012, p. 587-595.

Research output: Contribution to journalReview article

@article{66070f9ec033431090a8cc931bdcb16e,
title = "Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: A systematic review and meta-analysis",
abstract = "Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation in the small airways. The effect of inhaled corticosteroids (ICS) on lung inflammation in COPD remains uncertain. We sought to determine the effects of ICS on inflammatory indices in bronchial biopsies and bronchoalveolar lavage fluid of patients with COPD. Methods: We searched Medline, Embase, Cinahl, and the Cochrane database for randomized, controlled clinical trials that used bronchial biopsies and bronchoalveolar lavage to evaluate the effects of ICS in stable COPD. For each chosen study, we calculated the mean differences in the concentrations of inflammatory cells before and after treatment in both intervention and control groups. These values were then converted into standardized mean differences (SMD) to accommodate the differences in patient selection, clinical treatment, and biochemical procedures that were employed across the original studies. If significant heterogeneity was present (P, 0.1), then a random effects model was used to pool the original data; otherwise, a fixed effects model was used. Results: We identified eight original studies that met the inclusion criteria. Four studies used bronchial biopsies (n = 102 participants) and showed that ICS were effective in reducing CD4 and CD8 cell counts (SMD, -0.52 units and -0.66 units, 95{\%} confidence interval). The five studies used bronchoalveolar lavage fluid (n = 309), which together showed that ICS reduced neutrophil and lymphocyte counts (SMD, -0.64 units and -0.64 units, 95{\%} confidence interval). ICS on the other hand significantly increased macrophage counts (SMD, 0.68 units, 95{\%} confidence interval) in bronchoalveolar lavage fluid. Conclusion: ICS has important immunomodulatory effects in airways with COPD that may explain its beneficial effect on exacerbations and enhanced risk of pneumonia.",
keywords = "Bronchial biopsies, Bronchoalveolar lavage, Chronic obstructive pulmonary disease, Inflammation, Inflammatory markers, Inhaled corticosteroids, Meta-analysis",
author = "Rachel Jen and Rennard, {Stephen I.} and Sin, {Don D.}",
year = "2012",
month = "12",
day = "1",
doi = "10.2147/COPD.S32765",
language = "English (US)",
volume = "7",
pages = "587--595",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease

T2 - A systematic review and meta-analysis

AU - Jen, Rachel

AU - Rennard, Stephen I.

AU - Sin, Don D.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation in the small airways. The effect of inhaled corticosteroids (ICS) on lung inflammation in COPD remains uncertain. We sought to determine the effects of ICS on inflammatory indices in bronchial biopsies and bronchoalveolar lavage fluid of patients with COPD. Methods: We searched Medline, Embase, Cinahl, and the Cochrane database for randomized, controlled clinical trials that used bronchial biopsies and bronchoalveolar lavage to evaluate the effects of ICS in stable COPD. For each chosen study, we calculated the mean differences in the concentrations of inflammatory cells before and after treatment in both intervention and control groups. These values were then converted into standardized mean differences (SMD) to accommodate the differences in patient selection, clinical treatment, and biochemical procedures that were employed across the original studies. If significant heterogeneity was present (P, 0.1), then a random effects model was used to pool the original data; otherwise, a fixed effects model was used. Results: We identified eight original studies that met the inclusion criteria. Four studies used bronchial biopsies (n = 102 participants) and showed that ICS were effective in reducing CD4 and CD8 cell counts (SMD, -0.52 units and -0.66 units, 95% confidence interval). The five studies used bronchoalveolar lavage fluid (n = 309), which together showed that ICS reduced neutrophil and lymphocyte counts (SMD, -0.64 units and -0.64 units, 95% confidence interval). ICS on the other hand significantly increased macrophage counts (SMD, 0.68 units, 95% confidence interval) in bronchoalveolar lavage fluid. Conclusion: ICS has important immunomodulatory effects in airways with COPD that may explain its beneficial effect on exacerbations and enhanced risk of pneumonia.

AB - Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation in the small airways. The effect of inhaled corticosteroids (ICS) on lung inflammation in COPD remains uncertain. We sought to determine the effects of ICS on inflammatory indices in bronchial biopsies and bronchoalveolar lavage fluid of patients with COPD. Methods: We searched Medline, Embase, Cinahl, and the Cochrane database for randomized, controlled clinical trials that used bronchial biopsies and bronchoalveolar lavage to evaluate the effects of ICS in stable COPD. For each chosen study, we calculated the mean differences in the concentrations of inflammatory cells before and after treatment in both intervention and control groups. These values were then converted into standardized mean differences (SMD) to accommodate the differences in patient selection, clinical treatment, and biochemical procedures that were employed across the original studies. If significant heterogeneity was present (P, 0.1), then a random effects model was used to pool the original data; otherwise, a fixed effects model was used. Results: We identified eight original studies that met the inclusion criteria. Four studies used bronchial biopsies (n = 102 participants) and showed that ICS were effective in reducing CD4 and CD8 cell counts (SMD, -0.52 units and -0.66 units, 95% confidence interval). The five studies used bronchoalveolar lavage fluid (n = 309), which together showed that ICS reduced neutrophil and lymphocyte counts (SMD, -0.64 units and -0.64 units, 95% confidence interval). ICS on the other hand significantly increased macrophage counts (SMD, 0.68 units, 95% confidence interval) in bronchoalveolar lavage fluid. Conclusion: ICS has important immunomodulatory effects in airways with COPD that may explain its beneficial effect on exacerbations and enhanced risk of pneumonia.

KW - Bronchial biopsies

KW - Bronchoalveolar lavage

KW - Chronic obstructive pulmonary disease

KW - Inflammation

KW - Inflammatory markers

KW - Inhaled corticosteroids

KW - Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=84872236803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872236803&partnerID=8YFLogxK

U2 - 10.2147/COPD.S32765

DO - 10.2147/COPD.S32765

M3 - Review article

C2 - 23055709

AN - SCOPUS:84872236803

VL - 7

SP - 587

EP - 595

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -